Prime Medicine Inc (NASDAQ:PRME) has a beta value of 2.07 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $590.10M, closed the last trade at $4.92 per share which meant it gained $0.06 on the day or 1.23% during that session. The PRME stock price is -249.59% off its 52-week high price of $17.20 and 16.46% above the 52-week low of $4.11. The 3-month trading volume is 744.56K shares.

Prime Medicine Inc (NASDAQ:PRME) trade information

Sporting 1.23% in the green in last session, the stock has traded in the green over the last five days, when the PRME stock price touched $4.92 or saw a rise of 4.28%. Year-to-date, Prime Medicine Inc shares have moved -44.47%, while the 5-day performance has seen it change 2.50%. Over the past 30 days, the shares of Prime Medicine Inc (NASDAQ:PRME) have changed -27.22%.

Prime Medicine Inc (PRME) estimates and forecasts

Figures show that Prime Medicine Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -11.99% over the past 6 months, with this year growth rate of 11.33%, compared to 12.60% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -6.80% and 6.40% for the next quarter.

8 analysts offering their estimates for the company have set an average revenue estimate of $910k for the current quarter. 8 have an estimated revenue figure of $2.04 million for the next quarter concluding in Jun 2024.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -193.88% over the past 5 years.

PRME Dividends

Prime Medicine Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.